New drug aims to save kidneys: 3,000-Patient trial launches
NCT ID NCT06866236
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tests a new drug called QRX3 in 3,000 people with chronic kidney disease whose kidney function is declining. The goal is to see if QRX3 can improve kidney function and slow the need for dialysis. Participants take QRX3 capsules, and researchers measure changes in kidney filtration rates and protein levels in urine over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QRX-3 (a drug that targets kidney function)
What this could lead to
If successful, this could provide a new treatment option to slow kidney decline and reduce the need for dialysis in people with chronic kidney disease.
What could go wrong
This is an early-phase trial (phase 2/3) with a large but specific group of participants, so results may not apply to all kidney disease patients. The drug may not improve kidney function or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••